NCE-1 Intelligence & Market Opportunity

Jaypirca

Pirtobrutinib

Anticancer

Tablet

Jaypirca is a non-covalent BTK inhibitor used to treat adults with relapsed or refractory mantle cell lymphoma and chronic lymphocytic leukemia after prior treatments. It’s taken orally once daily.

Approval Date

27-Jan-23

NCE-1 Date

27-Jan-27

NCE Date

27-Jan-28

Commercial snapshot

Market performance & projections

Revenue ($M)

506

CAGR (%)

0.3724

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

828

2027

1112

2028

1384

2029

1795

2030

2163

2031

2547

2032

2917

Molecule profile

Details & specifications

Molecule

Pirtobrutinib

Innovator

LOXO ONCOLOGY INC

Dosage Form

Tablet

Strength

50 mg, 100 mg

Therapeutic Category

Anticancer

Usage

To treat relapsed or refractory mantle cell lymphoma in adults who have had at least two lines of systemic therapy, including a BTK inhibitor

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

What are the common side effects of Jaypirca?

How does Jaypirca work differently from other BTK inhibitors?

Common side effects of Jaypirca may include diarrhea, fatigue, and upper respiratory tract infections.

Jaypirca is a non-covalent (reversible) Bruton’s tyrosine kinase (BTK) inhibitor. This means that it continues to work even when cancer cells develop resistance to traditional covalent BTK inhibitors.